James Brumley
James Brumley (RSS)
InvestorPlace Contributor

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He's now primarily a freelance writer, tapping more than a decade's worth of broad experience to help investors get more out of the market.

Read complete bio
Recent Articles

3 Reasons the USPS Shouldn’t Become a Bank

Feb. 11, 2014, 11:57 am EDT – Every financial service name from Wal-Mart to Well Fargo to Cash America would be on the hot seat if the USPS gets the green light, but... More 

3 Reasons the Keurig Cold Won’t Rejuvenate KO Stock

Feb. 10, 2014, 8:30 am EDT – GMCR was catapulted when Coca-Cola inked a deal with Green Mountain, but that doesn't mean a Keurig Cold machine will do wonders for KO stock. More 

5 Cheap Stocks From the Pharmaceutical Industry

Feb. 6, 2014, 2:25 pm EDT – These five cheap stocks from the pharmaceutical world could make for a great low-priced addition to investment portfolios. More 

KORS Stock Still Worth the Price Tag

Feb. 5, 2014, 8:53 am EDT – KORS stock has smoked most other luxury brand stocks, but it's no fluke. Michael Kors is hitting the nail right on the head. More 

5 Ambitious Plans From AMZN: Which Will Work?

Feb. 4, 2014, 11:49 am EDT – Amazon has several irons in the fire, though not all of them are reasons to own AMZN stock. But some plans could be very good reasons to be an investor. More 

Facebook Users Are Getting Older … and That’s a Good Thing

Feb. 4, 2014, 6:00 am EDT – Owners of FB stock worried about aging Facebook users don't need to pull the plug on their position just yet. The numbers explain why. More 

Abercrombie & Fitch Is Stuck in the 90s

Feb. 3, 2014, 6:00 am EDT – Aeropostale, American Eagle, and Abercrombie & Fitch have managed to work their way into irrelevancy. More 

3D Printing Stocks: 2 You Want, 3 You Don’t

Jan. 30, 2014, 9:51 am EDT – 3D printer makers have had a tough go of things so far this year, but not all 3D printing stocks deserve to be benched. More 

For JCP Stock Holders, Proposed Poison Pill Isn’t Worth It

Jan. 29, 2014, 11:55 am EDT – The JCPenney Board of Directors makes a great case for its proposed poison pill, but there's a huge downside to it for JCP stock owners. More 

Medical Devices: 5 Healthcare Stocks to Buy

Jan. 28, 2014, 2:57 pm EDT – If President Obama's new tax on medical devices was supposed to be a problem for healthcare equipment makers, you wouldn't know it from these five companies. More